---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012488"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:47:34.787423+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals appoints Judith Matthews as CFO effective June 1, 2026

## Summary
- Judith Matthews will become CFO on June 1, 2026, succeeding James Gruber who remains through May 31 then six-month consulting.
- Annual base salary of $440,000, target bonus 45% of salary, one-time option for 37,000 shares vesting over 4 years.
- Matthews was previously CFO of Iterum Therapeutics (2015-2026) and VP Finance at Durata Therapeutics.
- Gruber to provide transition support via six-month consulting agreement.

## SEC filing metadata
- accession: 0001437749-26-012488
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926012488/0001437749-26-012488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926012488/eton20260413_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012488
- JSON: https://secwatch.observer/filing/0001437749-26-012488.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.